India's Biocon exits enzymes business

Biocon sells its enzymes business to Denmark's Novozymes for $115 million in an attempt to become a more focussed biotechnology player.

Indian biotechnology player Biocon announced on July 18 that it will sell its enzymes business to Novozymes of Denmark for $115 million.

Biocon is currently in the bio-pharmaceuticals, contract research, clinical research and enzymes businesses. Its enzymes division offers a range of industrial enzymes, food additives, process aids and enzymes for the juice and wine industries. The divestiture is designed to sharpen BioconÆs focus on its bio-pharmaceuticals business, which includes active pharmaceutical ingredients, biologicals and proprietary molecules.

Of the total...

FinanceAsia has updated its subscription model. Registered readers now have the opportunity to read five articles from our award-winning website for free. Please subscribe for unlimited access.

Click for more on: biocon | novozymes | enzymes

Print Edition

FinanceAsia Print Edition

EVENTS